#United States #ivWatch #Newport News #SmartTouch+ #IV Monitoring

ivWatch Takes a Major Step Forward with SmartTouch+™ Device

ivWatch, LLC, a company dedicated to improving safety in intravenous (IV) therapy, has recently announced the submission of a 510(k) filing to the U.S. Food and Drug Administration (FDA) for their groundbreaking SmartTouch+™ Sensor. This innovative technology aims to significantly expand the company's current capabilities in continuously monitoring IV therapy, specifically targeting applications related to infiltrations and extravasations in both clear and white-opaque infusates.

This filing comes in response to a pressing need in the medical field, as infiltrations and extravasations – which refer to the unintended administration of IV solutions into the surrounding tissue instead of directly into the vein – are among the most common complications associated with IV therapy. Despite being a frequent occurrence, these events often go unnoticed until substantial damage occurs. Current monitoring practices typically rely on visual and tactile inspection, which can lead to critical delays, sometimes allowing hours to pass before any complications are detected.

The introduction of the SmartTouch+ Sensor will specifically address the risks associated with white opaque infusions, such as total parenteral nutrition (TPN) and sedative medications like propofol. These substances can be particularly hazardous when extravasation occurs, potentially leading to severe tissue damage, requiring critical intervention. Erin Wendell, President of ivWatch, articulated the practical need for this advancement, emphasizing the financial burden hospitals face when managing severe extravasation injuries, which frequently result from the use of peripheral infusions involving white-opaque fluids.

The SmartTouch+ Sensor integrates seamlessly with the existing ivWatch Patient Monitor and boasts a remarkable capacity to perform over 18,000 checks per hour for any irregularities indicative of infiltration or extravasation. This proactive approach ensures that clinicians are alerted well before such complications become visually or tactically detectable, thereby allowing timely interventions that can minimize harm.

In various clinical settings, the risks associated with undetected infiltration can vary significantly. In neonatal intensive care units, for example, infants may receive TPN but lack the ability to communicate any discomfort at the IV site. Similarly, in surgical environments, lipid-based infusions and sedatives might obscure IV sites from visual monitoring due to drapes, making continuous oversight a challenge. For these vulnerable patient populations, the capacity to identify infiltration early can mean the difference between minor complications and serious injuries.

Once the sensor receives FDA clearance, it will cater to diverse patient demographics and integrate with standard IV dressings alongside existing clinical workflows. Its compact and flexible design ensures compatibility across various healthcare environments, including hospitals and infusion centers, thereby enhancing the safety protocols in place for cloudy infusions.

As the healthcare landscape becomes increasingly focused on patient safety, ivWatch's innovation reflects a significant commitment to mitigating IV-related incidents that can endanger patients. The company holds an impressive portfolio of patents and intellectual property concerning IV safety technology, with the SmartTouch+ sensor currently pending patent approval pending its ongoing review by the FDA. At present, the device is not FDA-cleared and remains unavailable for commercial distribution in the United States.

Founded in 2010, ivWatch is pioneering change in IV safety. As the standard practice remains that up to 50% of IV insertions can fail, often resulting in dire consequences such as dosing errors, nerve damage, or in the most tragic cases, fatalities, ivWatch strives to provide innovatively engineered solutions. This includes a first-of-its-kind FDA-cleared Class II medical device capable of continuous monitoring of peripheral IVs to aid the early detection of infiltration and extravasation events. To learn more about their mission and technology, readers can visit ivWatch's website.